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Introduction
The contribution R&D makes to economic growth has become 
both a political and a social issue in recent years. In today’s economy, 
knowledge is one of the main economic assets, and its management 
and protection have become the cornerstones of corporate strategy in 
industrialized nations [1]. The global economic crisis has led to a new 
political and social scenario in which governments take decisions every 
day that decide their country’s economic future. Nowadays, there is a 
widely held perception that the higher levels and rates of growth enjoyed 
by some domestic economies are attributable to the greater success 
those countries had in exploiting emerging technological opportunities 
[2]. It is therefore important to analyze the political determinants these 
countries have been applying over the course of many years. In turn, 
it is of interest to analyze not only the determinants of success but also 
the expediency of decisions that were made, and are still being made, in 
countries that are worse off in economic terms.
Since the mid-1980s, certain authors [3-6] have studied the 
concept of National Innovation System (NIS) in order to understand 
the interrelationships between technological development and the 
decisions of government institutions [7,8]. Since the early 1990s, there 
have been variations in the approach to this concept that now recognize 
the importance of developing autonomous innovation systems at local, 
regional, EU and even global level [9-12].
The aim of this article is therefore to identify the political, social and 
scientific reasons behind the current situation and the advancement 
of biotechnology in Spain. This issue is addressed using patents as an 
indicator of technological development. This study analyzes national 
patent applications registered in the SPTO, its property distribution 
and which are therefore legally protected only in Spain. The indicators 
most studies have so far used to evaluate science and technology 
systems are the patents registered in international bodies such as the 
European Patent Office (EPO), the United States Patent and Trademark 
Office (USPTO) or the Japan Patent Office (JPO). However, this study 
does not seek to draw a comparison at international level. We aim 
to describe, in as much detail as possible, the situation of a domestic 
biotechnology system and, in particular, the Spanish case. This paper 
proposes, among other indicators, the use of national patents in order 
to evaluate the science conducted in Public Research Organisms 
(PROs), and universities. According to current patent legislation, all 
public institutions are required to deposit their inventions as national 
patents before obtaining licenses with international coverage (for more 
detail, see article 122 of Spain’s Law 11/1986, of 20 March, on Patents; 
http://www.boe.es/buscar/doc.php?id=BOE-A-1986-7900). Therefore, 
national patent data recorded in the SPTO provide the latest and most 
reliable information for assessing the situation of any science and 
technology sector.
It is important to analyze the design and reconfiguration of 
innovation systems over the years in order to explain the extreme 
dependency between politics and science [12,13]. Moreover, Lundvall 
[14] affirms that the focus upon domestic systems “reflects the fact that 
national economies differ regarding the structure of their production 
system and regarding the general institutional set-up”.
The Spanish economy grew very quickly from the mid-1990s 
onwards, as did the country’s investment in R&D and its research 
capacity, measured in terms of the output of published work [15]. 
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Spain’s economy recorded a high rate of growth from the mid-1990s onwards. At the same time, the resources 
allocated to Research and Development (R&D) grew at a much faster pace than in other European Union (EU) 
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average growth in the EU was 0.46%. This circumstance, together with several sound policy decisions implemented 
between 2004 and 2009, ushered in a “golden age of Spanish biotechnology”. In terms of the national patent licenses 
issued by the Spanish Patent and Trademark Office (SPTO) between 2004 and 2009, the number in biotechnology 
grew from 84 to 151. However, the current economic situation in Spain, along with a series of political decisions 
taken over the past two or three years to cut spending on R&D, predicts a sharp downturn in the performance of 
Spanish biotechnology. This scenario makes Spain one of the best places to study the successes and failures of the 
management of science and allows transfer this experience to the other international regions. We need to analyze 
the influence of political decisions as a major factor with a bearing on the quality of science. 
Using patents as an indicator of scientific development, this paper analyzes the evolution of the biotechnology 
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This paper confirms the suggestion made by several authors [16,17] 
who attributed this progress to the increase in R&D investment and 
the application of an evaluation policy designed to stimulate scientific 
production and its international diffusion.
When looking at the annual growth rate of investment in R&D as 
a percentage of Gross Domestic Product (GDP) from 1994 onwards in 
Spain, we perceive a major effort to increase spending on this activity. 
Until 2004, this growth rate was 2.93% in Spain, compared to the EU 
average of 0.46%, 0.85% in the United States and 2.24% in Japan [18]. 
However, Spain’s starting point for investment in R&D was one of 
distinct disadvantage, and this growth in investment has not sufficed to 
reach the average EU investment in R&D relative to GDP. The Lisbon 
European Council (2000) declared that the average value of investment 
in R&D relative to GDP in the EU would be 3% by 2010. Spain, with 
its poor starting position, decided to set its own goal for investment in 
R&D by 2010 at 2% of its GDP [19]. Spain invested 1.37% of its GDP in 
R&D in 2010, while the EU average was 1.91%. Both are far from what 
was agreed in Lisbon in 2000 [20].
The current Spanish Law on Science, Technology and Innovation 
was enacted in 2011. There had previously been only one piece of 
legislation on this matter, being introduced in 1986 and laying the 
foundations for all science and technology plans developed in Spain 
thereafter. The 1986 law considered the lack of social cues and the 
absence of public intervention instruments for coordinating the scarce 
resources available for research [21]. Besides, this law submitted the 
development of a “National Innovation Plan” (NIP) for Scientific 
Research and Technological Development to government approval. 
This plan provides for multi-year periods, the main national objectives 
for R&D and the means for their realization. These plans are prepared 
every three or four years and seek to upgrade R&D to adapt to the 
socioeconomic situation of the moment and correct the mistakes of 
previous plans.
Apart from the economic decisions included in the different NIPs, 
it is important to analyze national idiosyncrasies: the size and internal 
organization of firms, inter-firm relationships, the role of the public 
sector, the institutional set-up of the financial sector, and the intensity 
and organization of R&D.
This paper explains how the decisions (economic and non-
economic) made in these NIPs can affect the development of 
biotechnology in Spain, especially in the public sector, as it has a greater 
presence in this country than the private sector.
Knowledge produced by academic scientists has been identified 
as one of the most important inputs for technological progress and 
economic growth. Publicly financed science feeds and supports 
innovation in the private sector, which in turn creates new jobs and 
generates income [22]. In the wake of the Lisbon European Council 
(2000), the trend among European countries has been for an increase 
in private sector spending on R&D. The target for 2010 was that 60% of 
national expenditure on R&D would be covered by companies. Spain 
is one of the world’s countries with the highest percentage of public 
investment in R&D, and therefore the lowest private investment. In 
2008, the percentage of Spanish investment in R&D contributed 
by private companies was 45.5%. The EU average was 55% and the 
figures for Japan and the US were 74.6% and 64.3%, respectively [18]. 
This situation has forced Spain to design a very strict system for the 
management of science and adjust the objectives of Spanish science and 
technology to profitable public investment. This profitability should 
begin by encouraging the patenting of the results of public research.
Much of the debate on public patenting has revolved around the 
question as to whether or not the results of the research by universities 
and Public Research Organizations (PROs) should be patented [22]. 
Countries with higher public investment in science and technology 
should create incentives for patents among public researchers. On 
the other hand, PROs and universities need to create technology 
transfer units that are efficient enough to manage and monetize their 
patents. Technology transfer units should be the ones to manage public 
patents because they are familiar with both the public sector’s complex 
organization and industry needs, and therefore act as intermediaries 
between scientists, inventors and companies.
To the extent that patents have become an important issue for 
universities and PROs, there might be an incentive to shift the resources 
towards more applied research and to those areas where patents are 
easily obtained [23,24].
Materials and Methods
The dataset on which the empirical analysis is based was compiled 
specifically for the purpose this study. The database has been constructed 
using data from all the biotechnology sections at the SPTO. Biotechnology 
patents are identified using the following list of International Patent 
Classification (IPC) codes: A01H1/00, A01H4/00, A61K38/00, A61K39/00, 
A61K48/00, C02F3/34, C07G(11/00,13/00,15/00), C07K(4/00,14/00,16/00
,17/00,19/00), C12M, C12N, C12P, C12Q, C12S, G01N27/327, G01N33(5
3,54,55,57,68,74,78,88,92) [25]. We analyzed the time period between 1990 
and 2010. 1990 is considered the starting point for patents in biotechnology 
at global level [26].
We decided to use data on Spanish national patents in order to 
compare this information with international Spanish data registered 
in other patent offices, such as EPO or USPTO, as indicators of science 
and technology quality.
Macroeconomic data on Spanish R&D were collected from Spain’s 
National Statistics Office. International macroeconomic data were 
obtained from OECD and Eurostat databases. In certain cases, the 
latest international data published by the OECD are prior to 2010.
Data for “status of patent” are used as indicator of the benefits 
that different organizations obtain from their patents as previously 
reported by Belda et al. [27]. Furthermore, we assume that a correct 
interpretation of these data allows detecting erroneous management 
policies.
Results and Discussion
The relationship between investment and quality of science seems 
obvious, and it has been studied at some length by Adams and Griliches 
[28] and Payne and Siow [29]. Belda et al. [27] has examined the 
relationship between Spanish R&D investment and the development of 
biotechnology in Spain (measured by patent applications in the SPTO). 
Now, they found that there is a close relationship between investment 
and results solely in the field of biotechnology (Figure 1A). However, 
when comparing the response of biotechnology to financial investment 
in R&D and the same response in other areas of science and technology, 
we have found a lower dependence between R&D investment and 
the overall performance of science and technology (Figure 1B). This 
response by the biotechnology sector and the importance of a proper 
management of biotechnology resources have already been studied and 
confirmed by Yang et al. [30].
The worldwide biotechnology industry is characterized by its 
large R&D investments, with uncertain results and frequently without 
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benefits [30]. However, the Spanish case seems quite different [27]. 
Figure 1A confirms a very close correlation between the total investment 
in R&D and national performance in biotechnological research. Due to 
low private investment in R&D in Spain, public spending on R&D is 
primarily responsible for the variations in scientific results. Figure 2 
shows where public research in Spain outperforms the results of the 
private sector nationwide. Spanish public research accumulated 1282 
patent applications from 1990 to 2011 (717 by universities and 565 by 
PROs, including CSIC–Spanish Council for Scientific Research), while 
Spanish biotechnology companies accounted for 389 in the same period. 
However, when comparing the data on national patent applications 
with the Spanish data from international offices such as the USPTO, the 
graph is inverted. In this case, from 1990 to 2009, Spanish biotechnology 
companies owned 167 patents, while universities and PROs (including 
CSIC) accounted for 32 and 35, [31]. Private companies devote their 
resources to obtaining patents with worldwide coverage. These results 
suggest a clear relationship whereby high domestic public investment 
involves a high scientific output in the public sphere whose industrial 
interest is generally limited to Spanish territory. These results confirm 
that the national patent applications made to the SPTO are a very 
reliable indicator of the state of biotechnology in Spain.
Using patents as an indicator of the quality of science, we seek 
an explanation for the variations in Spanish patent applications in 
political decisions on investment in R&D reflected in successive NIPs. 
Understanding the links between the actors involved in the innovation 
process (researchers, policymakers and science managers) is the key to 
improving a country’s performance in innovation [32]. 
According to Belda et al. [27], Figure 1A shows four periods of 
intense activity: 1992-1993, 1998-1999, 2000-2001 and 2005-2011 
(last date evaluated). The timeframe between 2001 and 2005 shows 
a long period of decline in the number of patent applications and, 
therefore, research activity in Spain. The reason may lie in the National 
Biotechnology Program, designed in 1996 and kept in force until 
1999. This program, rolled out in 1996 by the Spanish Ministry of the 
Economy and Innovation, focuses all its efforts on adapting Spain’s 
biotechnological research to the “European Framework Programme”. 
Scientific managers may well have failed in their remit to obtain 
profitable research outcomes. However, this phenomenon has also been 
observed both in the other EU member states and in the US, Japan and 
Canada. It is understood that this decline has been caused by several 
factors, such as the completion of the Human Genome Project in 1998, 
which led to a decrease in DNA-related patents from 2001 onwards, an 
economic crisis that affected the US biotechnology industry in 2000, 
and a change in patent laws rendered DNA patenting more restrictive 
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Figure 1A: Spanish biotechnology patent requests and Spanish investment in R&D, public and private investment.
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Figure 1B: Spanish general patent requests and Spanish investment in R&D, public and private investment.
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in this area [31]. Spanish biotechnology would be indirectly affected by 
these events.
Finally, Figure 1A shows sharp growth in biotechnology patent 
applications. Between 2005 and 2009, the number of biotechnology 
patents in Spain doubled (77 applications in 2005 and 151 in 2009). 
In order to explain this growth, an analysis was made of the latest 
NIP, which was in force between 2000 and 2003. It was the first plan 
containing specific instruments for biotechnology management. This 
NIP developed the “Program of Technical Research Promotion”, which 
considered the preferred specific thematic areas of funding of particular 
interest to the country. In addition, the “Ramón y Cajal” program was 
introduced to provide research grants for talented young researchers. 
Nevertheless, the momentum in the biotechnology sector may actually 
be due to the creation of two public foundations: “Spanish Foundation 
for Science and Technology” (FECYT) and “Genoma España”. Both act 
as agencies for monitoring the quality of science and its management. 
Genoma España also manages part of the resources allocated to 
biotechnology scientists in Spain and promotes and oversees the 
transfer of technology from universities and PROs to business. Several 
authors [33-35] confirm that the production of scientific research and 
technological innovation depends on the structure of the NIS and 
driving sectors, suitably supported by human and financial resources.
When R&D spending in the private sector exceeds the 
corresponding amount spent in the public sector, labor productivity 
tends to grow [36]. However, public engagement is vital for offsetting 
the absence of private venture capital in Spain.
Cases like the German NIS are flexible and consider the situation 
of the different regions. In this sense, regions like Bavaria have created 
public agencies that provide seed and early-stage capital. On the other 
hand, numerous private venture capital firms and investment banks are 
resident in the Munich area, so there is no need for public intervention 
in biotechnology development [12].
Therefore, encouraging private investment in research in Spain and 
stimulating the creation of companies (spin-offs) from the research 
system give stability to Spanish biotechnology. Data shown after 2005 
in Figure 1A confirm this premise. As in the German case, encouraging 
private investment in R&D in regions accumulating capital seems to 
make sense, although public bodies should probably be responsible for 
the development of biotechnology in those areas with less presence in 
the financial sector.
The private biotechnology sector pursues international patent 
protection, so it does not feature in the data on national patents. 
However, given that the public sector is the largest national patent 
owner, according to the SPTO, and public investment in R&D in Spain 
exceeds private investment, national patent data allowed us to analyze 
the management of research in the public biotechnology sector in 
Spain.
Figure 2 shows the distribution of the biotechnology patent 
applications filed in Spain since 1991, with 1282 biotechnology patent 
applications being made by the Spanish public sector, including 
universities, PROs and other Regional Research Centers (RRCs). The 
private sector filed 389. After breaking the public sector down into its 
main components, the following values were obtained: Universities, 
717; CSIC, 358; PROs (without CSIC), 81; and RRCs, 126.
Spanish public universities are exempt from patent fees, so in order 
to compare the results of the scientific performance of the public and 
private sectors, university patent data were eliminated. Without the 
contribution of public university patents, the number of public patents 
was 563. This figure is still higher than the private sector, but now the 
difference is smaller.
After using “status of patent” to explain the public and private 
management of patents, mismanagement in the Spanish public sector 
has been described [37]. It is assumed that patents are withdrawn by 
their owners when they do not provide benefits. Thus, the percentage 
of patents in force in an organization can be related to the benefit these 
organizations gain from their patents. However, high percentages of 
patents in force may also mean a low level of interest and the forgoing 
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Figure 2: Distribution of biotechnology patent requests in Spain. The public sector is divided into universities, CSIC (Spanish National Research Council), PROs 
(other national Public Research Organizations) and RRCs (Regional Research Centers). The private sector is divided into universities, spin-offs and private 
companies.
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of their exploitation by their owners and managers. This situation is 
particularly important in the case of public knowledge management.
Conclusions
This paper contributes to an understanding of the reasons behind 
the evolution of biotechnology in Spain. Due to Spain’s current 
financial woes, and also to the focus of its NIS, the public sector should 
be the target of studies of this nature. Although Spain has a widespread 
tendency to stimulate private investment in R&D, it is still a country 
in which the bulk of the spending is made by the public sector. 
R&D expenditure in Spain reached its zenith in 2008. The growth in 
investment in R&D from 2007 to 2008 was between 1.27% and 1.35% 
of GDP. At the same time, GDP grew from €1.053.537 million to 
€1.088.124 million. These data show that 2008 was the peak year in 
spending on R&D (in absolute terms) and headed Spain in the right 
direction for technological and industrial development. By contrast, 
investment in R&D in Spain has fallen from 1.39% of GDP in 2009 
(with a slightly lower GDP than in 2008) to 1.33% in 2011.
After confirming biotechnology as one of the sectors most sensitive 
to economic investment, the government has to intervene in the 
development of biotechnology. This intervention should not only be 
financial. The public authorities should foster technology transfer from 
universities and PROs to industry. In many cases, academic research 
is poor at perceiving the state of the industry. It should therefore 
stimulate the creation of spin-offs, as besides being an incentive for 
researchers, they would create new job opportunities and promote the 
creation of a powerful biotechnology industry that contributes to the 
country’s economic future. One of the key points in this matter is the 
rigidity with which the state manages patents. Easy handling of patents 
by TTOs may well boost the knowledge transfer process.
Compared with international patent data, the national patent data 
analyzed in this study suggest that the Spanish authorities need to 
internationalize and industrialize their science in order to recoup their 
investments in R&D. The results recorded by the private sector confirm 
that patents with only national protection are insufficient to complete 
the process from science to business. At the same time, these kinds of 
patents are confirmed as an accurate indicator of the quality of science 
in countries with large public investments.
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